RGRXD Projected Dividend Yield

RegeneRx Biopharmaceuticals Inc ( OTCBB : RGRXD )

RegeneRX Biopharmaceuticals is a biopharmaceutical company focused on the development of a therapeutic peptide, Thymosin beta 4 (Tß4), for tissue and organ protection, repair, and regeneration. Co. has formulated Tß4 into three product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue.

20 YEAR PERFORMANCE RESULTS